Reforgene named a 2025 Future Healthcare Top 100 company for the third consecutive year
Recently, the 2025 Future Healthcare Top 100 exhibition (2025VBEF), hosted by VBDATA, was successfully held in Suzhou. Themed "THE NOW: Critical Point", this edition interpreted the coexistence of "ice and fire" at the critical point and witnessed the pioneers who dare to stand in the present and break through boundaries. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was again selected into the 2025 Future Healthcare Top 100, Innovative Medicine and Biologics TOP100, following 2023 and 2024. Receiving this honor for three consecutive years is the recognition by industry experts and industry observation and analysis institutions of the professional hard power that Reforgene has accumulated over years in the field of innovative gene editing medicine R&D.
The so-called "critical point" is the inevitable result of the accumulation of countless small changes; like the lever of the times, once the threshold is crossed, even the smallest force can flip the entire structure. The critical point of innovative healthcare is also approaching. Together with peers in innovative healthcare, Reforgene will hold fast and break through at the critical point, adhere to the dual-drive strategy of breakthroughs in underlying gene editing technology and drug R&D, dedicate itself to the birth of curative medicines, and bring China's innovative solutions for genetic diseases and complex diseases to the world.
The Future Healthcare Top 100 list, founded in 2015 by VB100, VBDATA and Danke Research Institute, is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry. After eight years of practice and exploration, the "Future Healthcare Top 100" selection has received strong support and recognition from many investment institutions and enterprises, and has become an investment bellwether in the healthcare field, leading the development and investment trends of China's healthcare innovation now and for some time to come, providing reference for the subsequent financing of innovative enterprises.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.